Document is current

Article History

Received: 29 August 2024

Accepted: 27 September 2024

First Online: 5 November 2024

Declarations

:

: Lukas G. Reeß, Hadi Salih and Murat Delikaya have nothing to disclose. Friedemann Paul reports research support from the German Ministry of Education and Research (BMBF), the German Research Council (DFG), the Einstein Foundation, the Guthy Jackson Charitable Foundation, the EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer and Roche. He reports receiving consultation fees from Alexion, Roche, Horizon and Neuraxpharm. He also reports receiving speaker honoraria from Almirall, Bayer, Biogen, GlaxoSmithKline, Hexal, Merck, Sanofi Genzyme, Novartis, Viela Bio, UCB, Mitsubishi Tanabe, Celgene, the Guthy Jackson Foundation, Serono and Roche. He is an advisory board member for Celgene, Roche, UCB and Merck and an academic editor for PLOS ONE as well as an associate editor for Neurology Neuroimmunology & Neuroinflammation—all outside the submitted work. Frederike Cosima Oertel acknowledges current research grants by the Hertie Foundation, Novartis and the DFG-TWAS program that were not related to this project. Past fellowship support by the American Academy of Neurology and the National MS Society is also acknowledged, as are a past research grant from the DGN (Germany Neurology Association) and speaker honoraria from UCB. She is currently board member at the International MS Visual System Consortium (IMSVISUAL) and Section Editor for DGNeurologie.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.